Integrated cascade nanozyme remodels chondrocyte inflammatory microenvironment in temporomandibular joint osteoarthritis via inhibiting ROS‐NF‐κB and MAPK pathways

Zhongyin Zhang,Lichan Yuan,Yufeng Liu,Ruobing Wang,Yihong Zhang,Yan Yang,Hui Wei,Junqing Ma

DOI: https://doi.org/10.1002/adhm.202203195

IF: 10

2023-02-06

Advanced Healthcare Materials

Abstract:Temporomandibular joint osteoarthritis (TMJ OA) is a degenerative joint disease with no complete cure at present. Notably, the inflammatory microenvironment in TMJ OA is modulated by oxidative stress, which impacts cartilage metabolism, chondrocyte apoptosis, inflammatory cytokine release, and extracellular matrix (ECM) synthesis. Thus, we reasoned that reducing excess reactive oxygen species (ROS) in the chondrocyte microenvironment may be an effective therapeutic strategy for TMJ OA. Recently, cascade nanozymes, including Pt@PCN222‐Mn, have been exploited to treat ROS‐associated diseases. Nevertheless, cascade nanozymes have not been employed for TMJ OA therapy. To fill this gap, we explored whether the Pt@PCN222‐Mn cascade nanozyme could be applied to the treatment of TMJ OA. The in vitro results demonstrated that the Pt@PCN222‐Mn nanozyme can inhibit the production of inflammatory factors, the degradation of ECM, and the apoptosis of chondrocytes by inhibiting the ROS‐NFκB and MAPK signalling pathways. The in vivo results further demonstrated that the Pt@PCN222‐Mn nanozyme can delay the progression of TMJ OA in the rat unilateral anterior crossbite (UAC) model. We believe this work will provide insightful perspectives on the application of nanozymes in TMJ OA. This article is protected by copyright. All rights reserved

nanoscience & nanotechnology,engineering, biomedical,materials science, biomaterials